 |
|
TREATMENT OF POLYCYTHEMIA VERA WITH TRIETHYLENE MELAMINESummary of Thirty Cases
NATHAN ROSENTHAL, M.D.;
ROBERT L. ROSENTHAL, M.D.
AMA Arch Intern Med. 1952;90(3):379-388.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
THE PURPOSE of this paper is to present data on the treatment of polycythemia vera with triethylene melamine (T. E. M.), based on the study of 30 cases followed for an average period of more than one year. Triethylene melamine, a compound which has nitrogen-mustard-like action, has the advantage that it is effective upon oral administration. The development of triethylene melamine, its pharmacological properties, and its use in patients with lymphomas, leukemia, and various carcinomas have been extensively discussed in papers by Karnofsky and associates1 and Wright and co-workers.2 Because of its ease of administration and its depressant effects upon hematopoiesis, which appear to resemble those of nitrogen mustard (methyl-bis or tris [β-choroethyl] amine hydrochloride) and x-irradiation,3 it appeared that triethylene melamine might be of value in the treatment of polycythemia vera.
Emphasis upon the treatment of polycythemia by bone marrow inhibition is largely derived from the work of Lawrence,4
. . . [Full Text PDF of this Article]
Author Affiliations
NEW YORK
Dr. N. Rosenthal is Consulting Hematologist at the Mount Sinai Hospital and Attending Hematologist at Harlem Hospital. Dr. R. L. Rosenthal is a Fellow in Medicine, Levy Foundation, Beth Israel Hospital.
Footnotes
This work was performed on ambulatory patients in the hematological laboratory and practice of Dr. N. Rosenthal.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
